topotecan has been researched along with folic acid in 8 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 1 (12.50) | 29.6817 |
2010's | 6 (75.00) | 24.3611 |
2020's | 1 (12.50) | 2.80 |
Authors | Studies |
---|---|
Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
Beijnen, JH; Borst, P; Breedveld, P; Cipriani, G; Dahlhaus, F; de Wolf, CJ; Jansen, G; Kuil, A; Pluim, D; Scheffer, GL; Schellens, JH; van Eijndhoven, MA | 1 |
Bloomfield, A; Dorton, R; Guan, J; Leamon, CP; Nelson, M; Reddy, JA; Vetzel, M | 1 |
Matsumoto, K; Onda, T; Yaegashi, N | 1 |
Jain, A; Jain, SK | 1 |
Bloomfield, A; Dircksen, C; Dorton, R; Kleindl, P; Leamon, CP; Nelson, M; Reddy, JA; Santhapuram, H; Vetzel, M; Vlahov, IR | 1 |
Meng, B; Qu, W; Wang, S; Yu, Y | 1 |
Cui, H; Ma, Q; Shi, W; Xue, G; Zhang, J; Zhang, L | 1 |
2 review(s) available for topotecan and folic acid
Article | Year |
---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
Pharmacotherapy for recurrent ovarian cancer: current status and future perspectives.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Carboplatin; Carcinoma, Ovarian Epithelial; Deoxycytidine; Doxorubicin; Everolimus; Female; Folic Acid; Gemcitabine; Humans; Indazoles; Neoplasm Recurrence, Local; Neoplasms, Glandular and Epithelial; Nivolumab; Ovarian Neoplasms; Paclitaxel; Phthalazines; Piperazines; Poly(ADP-ribose) Polymerase Inhibitors; Polyethylene Glycols; Pyrimidines; Quinazolines; Recombinant Fusion Proteins; Sirolimus; Sulfonamides; Topotecan; TOR Serine-Threonine Kinases; Vinca Alkaloids | 2015 |
6 other study(ies) available for topotecan and folic acid
Article | Year |
---|---|
The effect of low pH on breast cancer resistance protein (ABCG2)-mediated transport of methotrexate, 7-hydroxymethotrexate, methotrexate diglutamate, folic acid, mitoxantrone, topotecan, and resveratrol in in vitro drug transport models.
Topics: Animals; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Biological Transport; Breast Neoplasms; Cell Line; Cell Line, Tumor; Dogs; Female; Folic Acid; Humans; Hydrogen-Ion Concentration; Kinetics; Liver; Methotrexate; Mitoxantrone; Neoplasm Proteins; Rabbits; Resveratrol; Stilbenes; Topotecan | 2007 |
Rational combination therapy of vintafolide (EC145) with commonly used chemotherapeutic drugs.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Cell Line, Tumor; Cell Proliferation; Cisplatin; Docetaxel; Dose-Response Relationship, Drug; Doxorubicin; Drug Synergism; Folic Acid; HeLa Cells; Humans; Irinotecan; Mice, Inbred BALB C; Mice, Inbred DBA; Mice, Nude; Neoplasms; Neoplasms, Experimental; Paclitaxel; Taxoids; Topotecan; Treatment Outcome; Vinca Alkaloids; Xenograft Model Antitumor Assays | 2014 |
Multipronged, strategic delivery of paclitaxel-topotecan using engineered liposomes to ovarian cancer.
Topics: Animals; Antineoplastic Agents, Phytogenic; Blood Cells; Calorimetry, Differential Scanning; Cell Line, Tumor; Drug Combinations; Drug Liberation; Drug Synergism; Female; Folic Acid; Humans; Liposomes; Mice; Mice, Inbred BALB C; Ovarian Neoplasms; Paclitaxel; Polyethylene Glycols; Topoisomerase I Inhibitors; Topotecan | 2016 |
Pre-clinical evaluation of EC1456, a folate-tubulysin anti-cancer therapeutic.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Cell Line, Tumor; Cisplatin; Docetaxel; Drug Evaluation, Preclinical; Folic Acid; Humans; Mice, Nude; Neoplasms; Oligopeptides; Paclitaxel; Pipecolic Acids; Topotecan; Tumor Burden; Xenograft Model Antitumor Assays | 2018 |
Folic acid-conjugated mesoporous silica nanoparticles for enhanced therapeutic efficacy of topotecan in retina cancers.
Topics: Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Shape; Endocytosis; Folic Acid; Humans; Nanoparticles; Porosity; Retinal Neoplasms; Silicon Dioxide; Topotecan; Treatment Outcome | 2018 |
Improved Therapeutic Efficacy of Topotecan Against A549 Lung Cancer Cells with Folate-targeted Topotecan Liposomes.
Topics: A549 Cells; Administration, Intravenous; Animals; Cell Survival; Female; Folate Receptors, GPI-Anchored; Folic Acid; Humans; Liposomes; Lung Neoplasms; Mice, Inbred BALB C; Mice, Nude; Polyethylene Glycols; Rats, Sprague-Dawley; Topoisomerase I Inhibitors; Topotecan | 2020 |